■ DORC International launched Eva Nexus, an integrated system with retina, cataract, and combined surgery capabilities. The platform’s features are aimed at improving surgical performance and efficiency, and include SmartIOP, the Eva Aveta trocar cannula system, and Eva Inicio, the first CE-marked and FDA 510(k)–cleared microinjection system. During a limited release, more than 1,500 procedures were performed with the platform; a randomized controlled trial of 250 cases with Eva Nexus is wrapping up.

The company said that SmartIOP infusion for cataract surgery allows lower infusion pressures, sustaining a stable anterior chamber. The platform improves phaco energy efficiency and reduces effective phaco time. The Eva Inicio microinjection system technology enables precise, ±1 psi control of sub-1-mL injections with cannula systems for subretinal injections. The Eva Aveta cannula offers smoother insertion; surgeons have reported improved wound sealing and performance, according to the company.